Basilea’s revenue grew year over year boosted by Cresemba and Zevtera

Basilea Pharmaceutica’s revenue grew of 31% for the full year, reaching CHF 133 million (€117M), the company said on Tuesday, noting it’s year-end cash position being at CHF 223 million.

The Swiss company said that the revenue from Cresemba and Zevtera increased 56% to CHF 82 million. The company said it expects strong revenue growth from Cresemba and Zevtera to CHF 100-110 million in 2019.

With the total cost and operating expenses of CHF156.7 in 2018, the company reported net loss of (CHF31.4 million compared to last year’s €19.4 million.

Basilea also pointed out positive derazantinib phase 2 interim results and collaboration with Roche on combination with Tecentriq.

David Veitch, Chief Executive Officer, said: “We continue to make great progress establishing Zevtera and in particular Cresemba, as global brands. We are very pleased with the strong sales performance in 2018. We have also significantly strengthened our pre-clinical and clinical oncology pipeline through in-licensing transactions. The encouraging interim derazantinib results in the registrational phase 2 study and the recently announced collaboration with Roche support the significant potential value in intrahepatic cholangiocarcinoma and urothelial cancer.”